Advancing ASO therapies from development to implementation
Nat Med
.
2024 Oct;30(10):2725-2726.
doi: 10.1038/s41591-024-03217-x.
Authors
Rebecca Schuele
1
2
,
Matthis Synofzik
2
3
,
Holm Graessner
4
,
Annemieke Aartsma-Rus
5
Affiliations
1
Division of Neurodegenerative Diseases, Department of Neurology, Heidelberg University Hospital and Faculty of Medicine, Heidelberg, Germany.
2
Center for Neurology and Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
3
German Center of Neurodegenerative Diseases (DZNE), Tübingen, Germany.
4
Centre for Rare Diseases and Institute for Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
5
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands.
[email protected]
.
PMID:
39271846
DOI:
10.1038/s41591-024-03217-x
No abstract available